Results 201 to 210 of about 106,022 (294)

Glucagon-like Peptide-1 Receptor Agonists in Rheumatoid Arthritis: A Scoping Review of Metabolic, Anti-Inflammatory, and Cardioprotective Effects. [PDF]

J Pers Med
Buonanno S, Gaggiano C, Baldi C, Cantarini L, Frediani B, Gentileschi S.   +5 more
europepmc   +1 more source

Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli‐D Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare the efficacy and safety of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with insulin degludec plus insulin aspart (IDegAsp) by baseline age, Type 2 diabetes (T2D) duration and glycated haemoglobin (HbA1c) in the Soli‐D study.
Saichun Zhang, Yunjuan Gu, Yu Cheng, Ying Hu, Bing Li, Agustina Alvarez, Felipe Lauand, Lydie Melas‐Melt, Minlu Zhang, Yini Jiang, Qin Du, Lei Kang, Yiming Mu, Weijun Gu, Hongyu Kuang   +14 more
wiley   +1 more source

Co-prescription of metformin and glucagon-like peptide-1 receptor agonists and metformin-associated lactic acidosis: A case series. [PDF]

Clin Nephrol Case Stud
Hussain H, Ali M, Lorlowhakarn K, Capistrano MC, Balakrishnan VS, Jaber BL.   +5 more
europepmc   +1 more source

Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6‐Month Claims Database Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Tirzepatide is a once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) approved in the US for the treatment of Type 2 diabetes (T2D), weight loss and obstructive sleep apnoea. This study aimed to assess the utilisation and effectiveness of tirzepatide among individuals in a large ...
Theresa Hunter Gibble, Malvika Venkataraman, Donna Mojdami, Carlos Vallarino, Grace Stockbower, Michael Grabner, Mythili Ananth, Karishma Desai   +7 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists in movement disorders: From Parkinson's disease to the broader spectrum - Mechanisms, evidence, and future directions. [PDF]

Clin Park Relat Disord
Dahshan A, Khalil MIM, El-Jaafary SI, Al Yamani A.   +3 more
europepmc   +1 more source

Severity of Cardiovascular Autonomic Neuropathy Is Linked to Increasing Levels of Circulating Proinflammatory Cytokines

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiovascular autonomic neuropathy (CAN) is a severe form of diabetic neuropathy affecting approximately one in five people with diabetes and is a major predictor of cardiovascular mortality. Low‐grade inflammation may contribute to CAN development, but the exact inflammatory factors associated with CAN remain unclear.
Michelle Damgaard, Marietta Kokla, Rebekka H. Gerwig, Hatice Isik Mizrak, Sofie Korsgaard Hecquet, Tik Muk, Gurjeet Kaur, Birgitte Brock, Christian Stevns Hansen, Joachim Størling   +9 more
wiley   +1 more source

Glucagon-like Peptide-1 Receptor Agonists in Liver Transplant Recipients: A Retrospective Cohort Study. [PDF]

Transplant Direct
Sheashaa H, Ibrahim R, Elshaer A, Pham HN, Mouhaffel R, Habib E, Abdelnabi M, Farina JM, Lester SJ, Simper D, Alsidawi S, Steidley ED, Aqel BA, Barnhill M, Kim WR, Ayoub C, Arsanjani R.   +16 more
europepmc   +1 more source

Real‐World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Tirzepatide has demonstrated substantial weight‐loss efficacy in clinical trials, but real‐world evidence from routine digital prescribing remains limited. Methods We conducted a retrospective cohort study of adults initiating tirzepatide for obesity via a UK digital prescribing service between March 2024 and July 2025. Linked order‐
Onayomi Rosenior‐Patten, Zoe Lees, Rebecca Rowe, Safia Hussain, Ehtasham Ahmad, Edward Brooke, Sophie Dix, Catriona Maybury   +7 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities. [PDF]

Front Immunol
Ciancio G, Maranini B, Sandri G, Amati G, Bortoluzzi A, Silvagni E, Govoni M, Giuggioli D.   +7 more
europepmc   +1 more source

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early‐Phase Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The management of the disease of obesity has been transformed by incretin‐based therapies; however, additional and alternative therapeutic strategies are needed to address its biological complexity. This narrative review examines the physiology of amylin and the emerging role of amylin‐based therapies in obesity management.
Abdulhameed Alhazmi, Carel W. le Roux
wiley   +1 more source